Annual EBITDA
-$765.00 K
+$114.00 K+12.97%
31 December 2023
Summary:
XTL Biopharmaceuticals annual earnings before interest, taxes, depreciation & amortization is currently -$765.00 thousand, with the most recent change of +$114.00 thousand (+12.97%) on 31 December 2023. During the last 3 years, it has risen by +$182.00 thousand (+19.22%). XTLB annual EBITDA is now -129.57% below its all-time high of $2.59 million, reached on 31 December 2009.XTLB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$501.00 K
-$147.00 K-22.69%
31 March 2024
Summary:
XTL Biopharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization is currently $501.00 thousand, with the most recent change of -$147.00 thousand (-22.69%) on 31 March 2024. Over the past year, it has increased by +$688.00 thousand (+367.91%). XTLB quarterly EBITDA is now -90.29% below its all-time high of $5.16 million, reached on 31 December 2009.XTLB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$630.00 K
+$1.40 M+182.35%
31 March 2024
Summary:
XTL Biopharmaceuticals TTM earnings before interest, taxes, depreciation & amortization is currently $630.00 thousand, with the most recent change of +$1.40 million (+182.35%) on 31 March 2024. Over the past year, it has increased by +$2.35 million (+136.73%). XTLB TTM EBITDA is now -88.21% below its all-time high of $5.34 million, reached on 31 December 2009.XTLB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XTLB EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.0% | +367.9% | +136.7% |
| 3 y3 years | +19.2% | +372.6% | +141.3% |
| 5 y5 years | +3.5% | +351.8% | +176.9% |
XTLB EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +25.7% | -22.7% | +156.0% | at high | +126.8% |
| 5 y | 5 years | at high | +25.7% | -22.7% | +143.8% | at high | +126.8% |
| alltime | all time | -129.6% | +97.0% | -90.3% | +101.9% | -88.2% | +101.9% |
XTL Biopharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2024 | - | $501.00 K(-22.7%) | $630.00 K(-182.4%) |
| Dec 2023 | -$765.00 K(-13.0%) | $648.00 K(-446.5%) | -$765.00 K(-55.4%) |
| Sept 2023 | - | -$187.00 K(-43.7%) | -$1.72 M(-26.9%) |
| June 2023 | - | -$332.00 K(-62.9%) | -$2.35 M(+2.5%) |
| Mar 2023 | - | -$894.00 K(+196.0%) | -$2.29 M(+160.1%) |
| Dec 2022 | -$879.00 K(-14.7%) | -$302.00 K(-63.1%) | -$880.00 K(+1.9%) |
| Sept 2022 | - | -$819.00 K(+198.9%) | -$864.00 K(-1516.4%) |
| June 2022 | - | -$274.00 K(-153.2%) | $61.00 K(-107.5%) |
| Mar 2022 | - | $515.00 K(-280.1%) | -$809.00 K(-48.0%) |
| Dec 2021 | -$1.03 M(+8.8%) | -$286.00 K(-369.8%) | -$1.56 M(+1.9%) |
| Sept 2021 | - | $106.00 K(-109.3%) | -$1.53 M(+24.9%) |
| June 2021 | - | -$1.14 M(+393.1%) | -$1.22 M(+22.1%) |
| Mar 2021 | - | -$232.00 K(-9.7%) | -$1.00 M(-2.4%) |
| Dec 2020 | -$947.00 K(+12.5%) | -$257.00 K(-162.7%) | -$1.03 M(+1.3%) |
| Sept 2020 | - | $410.00 K(-144.4%) | -$1.01 M(-37.5%) |
| June 2020 | - | -$923.00 K(+259.1%) | -$1.62 M(+80.3%) |
| Mar 2020 | - | -$257.00 K(+5.3%) | -$900.00 K(+6.9%) |
| Dec 2019 | -$842.00 K(+6.2%) | -$244.00 K(+22.6%) | -$842.00 K(+2.8%) |
| Sept 2019 | - | -$199.00 K(-0.5%) | -$819.00 K(+1.1%) |
| June 2019 | - | -$200.00 K(+0.5%) | -$810.00 K(-56.8%) |
| Mar 2019 | - | -$199.00 K(-10.0%) | -$1.87 M(+136.2%) |
| Dec 2018 | -$793.00 K(-36.4%) | -$221.00 K(+16.3%) | -$793.00 K(-43.0%) |
| Sept 2018 | - | -$190.00 K(-85.0%) | -$1.39 M(+57.8%) |
| June 2018 | - | -$1.26 M(-243.4%) | -$882.00 K(+1503.6%) |
| Mar 2018 | - | $881.00 K(-207.4%) | -$55.00 K(-95.6%) |
| Dec 2017 | -$1.25 M(-27.3%) | -$820.00 K(-356.3%) | -$1.25 M(+54.8%) |
| Sept 2017 | - | $320.00 K(-173.4%) | -$805.00 K(-42.9%) |
| June 2017 | - | -$436.00 K(+40.6%) | -$1.41 M(-2.0%) |
| Mar 2017 | - | -$310.00 K(-18.2%) | -$1.44 M(-15.6%) |
| Dec 2016 | -$1.71 M(-14.3%) | -$379.00 K(+33.0%) | -$1.70 M(-19.1%) |
| Sept 2016 | - | -$285.00 K(-38.7%) | -$2.11 M(-4.5%) |
| June 2016 | - | -$465.00 K(-19.1%) | -$2.21 M(-0.6%) |
| Mar 2016 | - | -$575.00 K(-26.4%) | -$2.22 M(+10.1%) |
| Dec 2015 | -$2.00 M(+1.6%) | -$781.00 K(+102.9%) | -$2.02 M(+6.2%) |
| Sept 2015 | - | -$385.00 K(-19.6%) | -$1.90 M(+1.6%) |
| June 2015 | - | -$479.00 K(+29.1%) | -$1.87 M(+6.1%) |
| Mar 2015 | - | -$371.00 K(-44.0%) | -$1.76 M(-10.2%) |
| Dec 2014 | -$1.97 M(+79.3%) | -$663.00 K(+86.2%) | -$1.96 M(+161.0%) |
| Sept 2014 | - | -$356.00 K(-4.3%) | -$752.00 K(-661.2%) |
| June 2014 | - | -$372.00 K(-35.0%) | $134.00 K(-120.4%) |
| Mar 2014 | - | -$572.00 K(-204.4%) | -$656.00 K(-40.3%) |
| Dec 2013 | -$1.10 M | $548.00 K(+3.4%) | -$1.10 M(-62.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2013 | - | $530.00 K(-145.6%) | -$2.94 M(-17.6%) |
| June 2013 | - | -$1.16 M(+14.6%) | -$3.57 M(+18.1%) |
| Mar 2013 | - | -$1.01 M(-21.6%) | -$3.02 M(+27.3%) |
| Dec 2012 | -$2.39 M(+112.1%) | -$1.29 M(+1233.0%) | -$2.37 M(+69.9%) |
| Sept 2012 | - | -$97.00 K(-84.3%) | -$1.40 M(-10.7%) |
| June 2012 | - | -$616.00 K(+67.8%) | -$1.56 M(+29.8%) |
| Mar 2012 | - | -$367.00 K(+15.8%) | -$1.21 M(+5.1%) |
| Dec 2011 | -$1.13 M(-9.8%) | -$317.00 K(+20.1%) | -$1.15 M(+1.3%) |
| Sept 2011 | - | -$264.00 K(+2.7%) | -$1.13 M(-1.9%) |
| June 2011 | - | -$257.00 K(-16.8%) | -$1.15 M(-4.7%) |
| Mar 2011 | - | -$309.00 K(+2.3%) | -$1.21 M(-1.9%) |
| Dec 2010 | -$1.25 M(-148.3%) | -$302.00 K(+5.6%) | -$1.23 M(-129.2%) |
| Sept 2010 | - | -$286.00 K(-8.9%) | $4.23 M(-0.4%) |
| June 2010 | - | -$314.00 K(-5.4%) | $4.24 M(+26.7%) |
| Mar 2010 | - | -$332.00 K(-106.4%) | $3.35 M(-37.3%) |
| Dec 2009 | $2.59 M(-114.1%) | $5.16 M(-2004.1%) | $5.34 M(-164.5%) |
| Sept 2009 | - | -$271.00 K(-77.6%) | -$8.28 M(-10.1%) |
| June 2009 | - | -$1.21 M(-172.7%) | -$9.21 M(-20.8%) |
| Mar 2009 | - | $1.66 M(-119.7%) | -$11.63 M(+2.7%) |
| Dec 2008 | -$18.40 M(-28.2%) | -$8.46 M(+605.3%) | -$11.32 M(-61.6%) |
| Sept 2008 | - | -$1.20 M(-66.9%) | -$29.50 M(+5.1%) |
| June 2008 | - | -$3.63 M(-284.3%) | -$28.08 M(-12.4%) |
| Mar 2008 | - | $1.97 M(-107.4%) | -$32.05 M(-5.5%) |
| Dec 2007 | -$25.63 M(+62.2%) | -$26.64 M(<-9900.0%) | -$33.91 M(+43.4%) |
| Sept 2007 | - | $226.00 K(-103.0%) | -$23.65 M(-0.5%) |
| June 2007 | - | -$7.61 M(-6772.8%) | -$23.77 M(+19.3%) |
| Mar 2007 | - | $114.00 K(-100.7%) | -$19.91 M(0.0%) |
| Dec 2006 | -$15.80 M(+27.9%) | -$16.39 M(<-9900.0%) | -$19.91 M(+4.7%) |
| Sept 2006 | - | $114.00 K(-103.0%) | -$19.03 M(+1.0%) |
| June 2006 | - | -$3.75 M(-3393.0%) | -$18.84 M(+6.9%) |
| Mar 2006 | - | $114.00 K(-100.7%) | -$17.63 M(+7.2%) |
| Dec 2005 | -$12.36 M(-24.9%) | -$15.50 M(-5354.2%) | -$16.44 M(-19.0%) |
| Sept 2005 | - | $295.00 K(-111.6%) | -$20.31 M(+2.9%) |
| June 2005 | - | -$2.54 M(-294.8%) | -$19.74 M(-11.3%) |
| Mar 2005 | - | $1.30 M(-106.7%) | -$22.25 M(-1.9%) |
| Dec 2004 | -$16.46 M(+16.5%) | -$19.37 M(-2341.7%) | -$22.69 M(+582.3%) |
| Sept 2004 | - | $864.00 K(-117.1%) | -$3.33 M(-20.6%) |
| June 2004 | - | -$5.05 M(-685.0%) | -$4.19 M(-585.0%) |
| Mar 2004 | - | $864.00 K | $864.00 K |
| Dec 2003 | -$14.12 M(-20.3%) | - | - |
| Dec 2002 | -$17.71 M(+17.1%) | - | - |
| Dec 2001 | -$15.12 M | - | - |
FAQ
- What is XTL Biopharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals annual EBITDA year-on-year change?
- What is XTL Biopharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals quarterly EBITDA year-on-year change?
- What is XTL Biopharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals TTM EBITDA year-on-year change?
What is XTL Biopharmaceuticals annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of XTLB is -$765.00 K
What is the all time high annual EBITDA for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high annual earnings before interest, taxes, depreciation & amortization is $2.59 M
What is XTL Biopharmaceuticals annual EBITDA year-on-year change?
Over the past year, XTLB annual earnings before interest, taxes, depreciation & amortization has changed by +$114.00 K (+12.97%)
What is XTL Biopharmaceuticals quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of XTLB is $501.00 K
What is the all time high quarterly EBITDA for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high quarterly earnings before interest, taxes, depreciation & amortization is $5.16 M
What is XTL Biopharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, XTLB quarterly earnings before interest, taxes, depreciation & amortization has changed by +$688.00 K (+367.91%)
What is XTL Biopharmaceuticals TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of XTLB is $630.00 K
What is the all time high TTM EBITDA for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high TTM earnings before interest, taxes, depreciation & amortization is $5.34 M
What is XTL Biopharmaceuticals TTM EBITDA year-on-year change?
Over the past year, XTLB TTM earnings before interest, taxes, depreciation & amortization has changed by +$2.35 M (+136.73%)